ADA: Diabetes Duo Merck & Pfizer Report Positive PhIII Data For Investigational SGLT-2
Executive Summary
Merck & Co. Inc. and Pfizer Inc.'s investigational oral SGLT-2 inhibitor, ertugliflozin, has met its primary endpoints in two Phase III studies in type 2 diabetes patients – now the pair are continuing development with an 8,000 patient cardiovascular (CV) outcomes trial and plan to file the drug in US by the year end.
You may also be interested in...
Merck & Co, Pfizer Ertugliflozin Combo Data Beef Up Profile
Merck & Co and Pfizer release new combo data for their investigational SGLT2 inhibitor at the ADA – combinations will be key to the latecomer's overall success.
Keeping Track: US FDA Accepts Ertugliflozin, Extends Reviews Of Abaloparatide, New Keytruda Claim
The latest drug development news and highlights from our FDA Performance Tracker.
With VERTIS SITA2 On Board, Merck Eyes Broad Initial Approval For Ertugliflozin
In an interview at the European Association for the Study of Diabetes meeting, Merck exec Sam Engel explains the rationale behind the clinical trial strategy for the SGLT-2 inhibitor ertugliflozin, as it gears up with partner Pfizer for filings by the end of this year.